Hemakim, Cerus' distributor for Turkey, has entered into a collaboration agreement to supply its Intercept Blood system to Florence Nightingale Hospital Group.
The Florence Nightingale Hospital provides patient-centered and specialized healthcare by integrating education, research and technology with clinical care.
Florence Nightingale Transfusion Center director and associate professor Hulya Bilgen said with the adoption of the Intercept Blood system, the center can provide patients with safe and effective blood products, consistent with its mission to use products to continuously improve patient care.
"We strive to provide our patients and their families with the best the world can offer, with service from a qualified and experienced clinical staff," Bilgen added.
Cerus president Caspar Hogeboom said the company's Intercept system meets Florence Nightingale Hospital's demanding standards for healthcare technologies.
"Including Turkey, customers in 18 countries have chosen the INTERCEPT Blood System to protect patients from transfusion-transmitted diseases," Hogeboom added.
